Everand Logo

Welcome to Everand!

  • STAT

    3 China biotech stories to watch in 2019

    In 2018, biotech in China generated relentless news. What's next for 2019?
    by Rebecca Robbins Dec 26, 2018 2 minutes

    As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here. 

    This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
    A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
    Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
    Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.

    Related Books & Audiobooks